Poll

RN Practice Poll #2: MTX Plus Anti-TNF Fails in RA. What Next?

Last week's poll asked what you'd do for a rheumatoid arthritis patient unhelped by methotrexate. That strategy has failed too: What next? Weigh in here with your best choice.

Thank you for joining the weekly Practice Poll, our effort to gauge current practice regarding unresolved issues in rheumatology.

Last week's poll considered what to do after a methotrexate failure in RA. There's still time to check in and enter your opinion, if you haven't yet done so. This week we move along with the same patient. If that strategy fails, what will you try next?

See also:

RN Practice Poll #1: Your Strategy After MTX Fails in RA

 

In an RA patient, after the first anti TNF + MTX fails, what do you change to?

Another anti-TNF
Tocilizumab (Actemra) IV or subQ
Abatacept (Orencia) IV or subQ
Rituximab (Rituxan)
Add leflunomide (Arava)
Switch to oral JAK inhibitor
Stop anti-TNF and add hydroxychloroquine and sulfasalazine
Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.